Evive Biotech is an integrated biotech company developing therapeutic biologics. Products under development are mainly aimed at unsolved medical problems, such as oncology, inflammation, and autoimmune diseases. The company was formerly known as Generon Biomed, Inc. and changed its name to Evive Biotech in June 2020. The company was founded in 2004 and is based in Singapore, Singapore.

Bluebird Bio is developing gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of treatments for diseases with few or no clinical options. The company's approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy.

Achilles Therapeutics (NASDAQ: ACHL) is a biopharmaceutical company. It develops personalized T cell therapies targeting neoantigens protein markers that are present on the surface of a cancer cell and can be detected by the immune system. It was founded in 2016 and is based in London, United Kingdom.

Audentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Juno Therapeutics is a clinical-stage company that brings together three cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute – in a partnership to advance a broad pipeline of immunotherapies. Juno will build on the foundation of immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. The company's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.